MedTrace Logo

MRI-based Computer Aided Diagnosis Software (V1) for Glioma

NCT05739500 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-02-22

No results posted yet for this study

Summary

The goal of this multi-center clinical trial is to evaluate the effectiveness of MRI-based computer-aided diagnosis software (V1) for glioma segmentation, gene prediction, and tumor grading. Machine learning methods such as high-precision tumor segmentation and classification and discrimination modeling can further optimize the non-invasive molecular diagnosis and prognosis prediction. The main question it aims to answer is whether the software can predict the molecular type and the prognosis quickly and correctly. The results will be compared with the real-world clinical data double-blindly. Finally, form a set of user-friendly automatic glioma diagnosis and treatment systems for clinics.

Conditions

Interventions

OTHER

no intervention, just observation

Sponsors & Collaborators

  • Huashan Hospital

    collaborator OTHER

  • Fudan University

    collaborator OTHER

  • Mingge LLC

    lead INDUSTRY

Principal Investigators

  • Zhifeng Shi, MD. · Huashan Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2025-11-23
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05739500 on ClinicalTrials.gov